eribulin

Ligand id: 6813

Name: eribulin

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: eribulin

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 12
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 146.39
Molecular weight 729.41
XLogP 0.56
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
An anticancer drug approved to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease, including both anthracycline- and taxane-based chemotherapies.
Following FDA orphan drug designation and priority review, the FDA expanded approval to include treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen in January 2016.
Mechanism Of Action and Pharmacodynamic Effects
A microtubule inhibitor isolated from the marine sponge Halichondria okadai.